# Antipsychotic and Motor Effects of ACP-103 When Administered in Combination With Haloperidol and Risperidone

> **NCT00361166** · PHASE2 · COMPLETED · sponsor: **ACADIA Pharmaceuticals Inc.** · enrollment: 400 (—)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** ACP-103

## Key facts

- **NCT ID:** NCT00361166
- **Lead sponsor:** ACADIA Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-08
- **Primary completion:** —
- **Final completion:** 2007-03
- **Target enrollment:** 400 (—)
- **Last updated:** 2007-03-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00361166

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00361166, "Antipsychotic and Motor Effects of ACP-103 When Administered in Combination With Haloperidol and Risperidone". Retrieved via MORVS 2026-10-19 from https://api.morvs.ai/clinical/NCT00361166. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*